肌炎临床试验中的种族、民族、性别与地域多样性
该系统综述评估2010至2023年发表的19项特发性炎症性肌病随机临床试验,发现种族恰当报告率为58%,黑种人、亚裔和西班牙裔或拉丁裔参与者分别占3%、7%和2%,仅26%报告民族,90%试验女性参与者超过45%,美国站点多在大都市区,无南美洲或非洲站点。
要点
- 19项特发性炎症性肌病随机临床试验中种族恰当报告率为58%,民族报告率仅26%。
- 黑种人、亚裔和西班牙裔或拉丁裔参与者分别占入组者的3%、7%和2%。
- 90%试验女性参与者超过45%,美国站点无位于非大都市区,仅31%位于医疗服务不足地区。
核心结论
- 特发性炎症性肌病随机临床试验的种族、民族和地域代表性仍是关键问题,报告不足和代表性有限引发对研究结果通用性的担忧。
研究设计与样本
- 系统文献综述评估2010年至2023年发表的19项特发性炎症性肌病随机临床试验,按性别与性别公平研究指南分析性别报告,种族和民族恰当报告定义为报告所有试验参与者,国家按人类发展指数分类,美国站点按国家卫生统计中心城乡分类方案和医疗服务不足地区分组。
主要发现
- 19项随机临床试验中种族恰当报告率为58%,黑种人、亚裔和西班牙裔或拉丁裔参与者分别占入组者的3%、7%和2%。
- 民族仅在26%的随机临床试验中报告,16%将种族和民族混为一谈,种族和民族代表性的时间趋势显示鼓励性结果。
- 大多数试验(90%)女性参与者超过45%,站点地域包括北美、欧洲、亚洲和澳大拉西亚,南美洲或非洲无站点。
- 美国大多数站点位于大都市区,非大都市区无站点,仅31%位于医疗服务不足地区。
关键数值与推荐
- 种族恰当报告定义为报告所有试验参与者的种族,19项随机临床试验中58%达到该标准。
- 民族报告率26%,16%的随机临床试验将种族和民族混为一谈。
- 黑种人、亚裔和西班牙裔或拉丁裔参与者分别占入组者的3%、7%和2%。
- 90%的随机临床试验女性参与者超过45%。
- 美国站点中仅31%位于医疗服务不足地区,非大都市区无站点。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The number of randomized clinical trials (RCTs) with patients with idiopathic inflammatory myopathies (IIMs) has grown exponentially over the last decade. Race, ethnicity, and sex reporting and representation of participants as well as the geographic distribution of enrolling sites in IIM RCTs are unknown. This information can provide critical insights into the current state of enrollment practices and generalizability in IIM RCTs. METHODS: A systematic literature review assessed IIM RCTs published between 2010 to 2023. Sex and gender reporting was analyzed per Sex and Gender Equity in Research guidelines. Appropriate reporting of race and ethnicity was defined as reporting them for all trial participants. Countries were categorized based on the Human Development Index. US enrollment sites were grouped using the National Center for Health Statistics Urban-Rural Classification Scheme and medically underserved areas (MUAs). RESULTS: Of the 19 RCTs included, race was appropriately reported in 58%. Black, Asian, and Hispanic or Latino participants represented 3%, 7%, and 2% of the enrollees, respectively. Ethnicity was only reported in 26% of RCTs, and 16% conflated race and ethnicity. Temporal trends showed encouraging results for race and ethnicity representation. Most trials (90%) had greater than 45% women participants. Geographic regions of sites included North America, Europe, Asia, and Australasia, with no sites in South America or Africa. The majority of US sites were located in large metropolitan areas, whereas none were in nonmetropolitan areas, and only 31% in MUAs. CONCLUSION: Racial, ethnic, and geographic representation in IIM RCTs remains a critical issue. Inadequate reporting of race and ethnicity and limited sociodemographic and geographic representation of participants raise concerns about the generalizability of findings of IIM RCTs.
引用
- Lomanto Silva R, Tumba MC, Gupta S, et al. Racial, Ethnic, Sex, and Geographical Diversity in Myositis Clinical Trials. Arthritis Care Res (Hoboken). 2025. PMID: 40099495. doi:10.1002/acr.25525
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。